Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLIUM: Cefepime-Enmetazobactam in cUTI/AP
NCT03687255Phase 3Completed
- Sponsor
- Allecra Therapeutics
- Start
- Sep 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of enmetazobactam in complicated urinary tract infection (cUTI) and acute pyelonephritis (2 arms), sponsored by Allecra Therapeutics. Primary endpoint: Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC). Started Sep 2018; status: completed.
02
Drugs
enmetazobactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT03687255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687255.